PeptideStack
5.2kquestions
20kanswers
220users

What did the placebo arm of SOUL report for dizziness?

Asked 9 Oct 2025Modified 10 months agoViewed 6.8k times
12

What I have: SOUL · dizziness.

I would like help reading this properly rather than being told what conclusion to reach.

I have the full report including the method section, so I can quote specifics if that helps.

How should I read this, and where are the traps?

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questionsharm-reduction
harm-reduction

Reducing avoidable risk where a decision has already been made: independent verification before use, sterility practice, dose arithmetic checked…

472 questions
shareeditfollowflag
HL
askedharriet_lonsdale35k1389 Oct 2025
6Is that the primary endpoint or a secondary one? They get quoted interchangeably. – h_pergande 5 months ago
7Do you have the population it was measured in? The figure moves a lot between them. – s_kalniete 6 months ago
add a comment

No answers yet

This question has not been answered. It has been viewed 6.8k times, which suggests the question is of interest and the answer is not obvious. If you can answer it with a source or a worked calculation, it will be read. See how to ask and answer.
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.